Loading...
The 2022 American Society of Clinical Oncology (ASCO) annual meeting, held in Chicago June 3 to 7, highlighted important advances in treatment across a broad spectrum of gastrointestinal malignancies. Here, Associate Editor Dr. David H. Ilson reviews key trials. Meeting abstracts can be viewed in the ASCO meeting library.
Cercek and colleagues presented potentially practice-changing findings on use of the anti PD-1 agent dostarlimab as the primary treatment for MSI-high locally advanced rectal cancer (abstract LBA5). In the phase 2 trial, adults with stage II or III disease received intravenous dostarlimab (500 mg) alone every 3 weeks for 6 months, to be followed by chemor…